Yarra 1.8 µm SEC-X300 has a separation range of 10K to 700KDa and is for separating and characterizing mAb (monoclonal antibody) aggregates, ADCs (antibody drug conjugates) and biosimilars in drug discovery and development research.
The HMW focus of the SEC-X300 complements the low molecular weight range (1K-450 kDa) of the existing Yarra 1.8 µm SEC-X150 column, said the firm.
The SEC-X150 and -X300 media are available in 150 and 300mm column lengths.
Phenomenex said the columns typically operate at backpressures below 3,500 psi and offer improved performance (greater resolution, better peak shape and faster analysis time) compared to existing 3 µm and 5 µm GFC/SEC column methods on HPLC systems.
Simon Lomas, strategic marketing manager at Phenomenex, said the columns feature greater media and hardware inertness to overcome sample adsorption.
"Yarra 1.8 µm SEC-X300 and -X150 were expertly developed and fine-tuned to offer our customers a wider applicability for popular biomolecule separations such as mAb fragmentation and ADC characterization," he said.
Phenomenex helps with screening and confirmatory methods for hazards including mycotoxins, environmental and process contaminants, food contact materials, pesticides and allergens.
It also has a portfolio of sample preparation products, UHPLC/HPLC, LC/MS, and GC/MS columns along with application support and method development services.